Treatments for Patients with Metastatic Castration-resistant Prostate Cancer Who Previously Received Triplet Therapy at the Metastatic Hormone-sensitive Stage

Yohann Loriot; Karim Fizazi

doi:10.1016/j.euf.2024.09.017

Treatments for Patients with Metastatic Castration-resistant Prostate Cancer Who Previously Received Triplet Therapy at the Metastatic Hormone-sensitive Stage

Eur Urol Focus. 2024 Jul;10(4):511-513. doi: 10.1016/j.euf.2024.09.017. Epub 2024 Oct 18.

Authors

Yohann Loriot¹, Karim Fizazi²

Affiliations

¹ Department of Cancer Medicine, Gustave Roussy, Université Paris-Saclay, Villejuif, France. Electronic address: yohann.loriot@gustaveroussy.fr.
² Department of Cancer Medicine, Gustave Roussy, Université Paris-Saclay, Villejuif, France.

PMID: 39424466
DOI: 10.1016/j.euf.2024.09.017

Abstract

The level of evidence for the management of prostate cancer progressing after triplet therapy is currently low. Molecular profiling of patients and enrolment in clinical trials are strongly recommended.

MeSH terms

Androgen Antagonists / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Humans
Male
Neoplasm Metastasis
Neoplasm Staging
Prostatic Neoplasms / drug therapy
Prostatic Neoplasms / pathology
Prostatic Neoplasms, Castration-Resistant* / drug therapy
Prostatic Neoplasms, Castration-Resistant* / pathology

Substances

Androgen Antagonists